MP22-12 DNA METHYLATION-BASED URINE ASSAY FOR DETECTION AND MONITORING OF BLADDER CANCER

Abstract

You have accessJournal of UrologyBladder Cancer: Detection & Screening1 Apr 2014MP22-12 DNA METHYLATION-BASED URINE ASSAY FOR DETECTION AND MONITORING OF BLADDER CANCER Jacob Ramon, Zohar Dotan, Abed Elhalim Darawsha, and Ilan Leibovitch Jacob RamonJacob Ramon More articles by this author , Zohar DotanZohar Dotan More articles by this author , Abed Elhalim DarawshaAbed Elhalim Darawsha More articles by this author , and Ilan LeibovitchIlan Leibovitch More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.860AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Bladder cancer is routinely detected and monitored by cystoscopy and urine cytology. Urine cytology assay is limited because of its low sensitivity (especially for low-grade tumors). Nevertheless, it is highly specific and can occasionally detect tumors that are missed by cystoscopy. Several alternative molecular assays were previously developed with the aim of complementing and/or replacing urine cytology, however, they also failed to reach high sensitivity and/or specificity and therefore were not widely used. In this study we describe a new approach for cancer detection in urine samples based upon epigenetic changes. This assay produces a DNA methylation "fingerprint" for urine. METHODS The assay ( "Bladder EpiCheck") is based on methylation-sensitive restriction of DNA in urine followed by quantitative amplification of 15 genomic loci that are hyper-methylated in bladder cancer. The resulting “fingerprint” is automatically analyzed by dedicated software that outputs the diagnosis and provides a quantitative EpiScore. The assay was developed on 109 urine samples from bladder cancer patients – 69 with and 40 without currently active disease. RESULTS The assay was tested on a “fresh batch” of 67 samples and detected 94% (including all high grade) tumors at a specificity of 84%. Using an alternative cut-off value the assay detected 81% of tumors at a specificity of 96%. CONCLUSIONS: “Bladder EpiCheck” is a powerful new non-invasive tool for bladder cancer detection and monitoring. Further studies are required to approve its high sensitivity and specificity. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e239 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Jacob Ramon More articles by this author Zohar Dotan More articles by this author Abed Elhalim Darawsha More articles by this author Ilan Leibovitch More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...